PubMed Health⌕ Search

Biomedical subjects

Anna Green

Publications and source records attributed to Anna Green.

4 recordsLinked to original sources
PubMed2026

Genomic Medicine Sweden: Advancing precision medicine at the national level.

High-throughput sequencing has transformed clinical diagnostics of rare diseases (RD), cancer and infectious diseases by enabling the identification of disease-causing genetic alterations and facilitating individualised treatment and care. In response to these advances, Genomic Medicine Sweden (GMS) was established in 2017 as a national collaborative effort to accelerate implementation of genomics-based precision medicine within Sweden's regionally organized, publicly funded healthcare system. GMS brings together the seven university healthcare regions and their associated medical faculties, in collaboration with healthcare regions across Sweden, Science for Life Laboratory, patient organizations, industry and governmental agencies. Activities are coordinated through national disease-specific expert groups, supported by cross-cutting functions in bioinformatics, health economics, ethics, education and patient engagement. At the operational level, seven Genomic Medicine Centres, embedded at university hospitals, develop and deliver harmonised genomic diagnostics nationwide. The National Genomics Platform provides secure infrastructure for large-scale data storage, analysis, and national and international data sharing. Following initial project-based funding, GMS now receives long-term governmental support. This review describes the national implementation of genomic-based precision diagnostics, discusses challenges and lessons learnt, and highlights key milestones across disease areas, including whole-genome sequencing in RD and paediatric cancer, comprehensive genomic profiling of haematological malignancies and solid tumours, pathogen genomics in microbiology, pharmacogenomic testing and emerging applications of polygenic risk scores in complex diseases. Collectively, these efforts have contributed to more than 500,000 genomic tests being performed within Swedish healthcare between 2017 and 2025. Finally, we outline future diagnostic needs and priority areas to ensure sustainable, scalable and equitable access to precision medicine.

Precision Medicine↗
PubMed2004

Bridging the gap between the intensive care unit and general wards-the ICU Liaison Nurse.

The acute care system in our public hospitals has seen an increase in acuity for multiday patients with associated pressure on access to the intensive care unit (ICU) beds for both elective and emergency patients. When an ICU bed has not been available at this hospital, it has resulted in elective surgery being cancelled and/or emergency patients requiring an ICU admission being transferred to other hospitals. Apart from the problems either of these situations can cause to patients and their families, both government and hospital managements expect that access to an ICU (or other) bed will be available for patients in our community who require this level of care. To maximise access to our ICU beds it was necessary to ensure that length of stay (LOS) in ICU was kept to the minimum required for each individual patient and that re-admission rates to ICU for preventable complications were reduced. This paper relates our experience of developing and introducing an advanced practice nursing position (the ICU Liaison Nurse) in 1998, to oversee the transition of patients discharged from ICU to the general wards. Between 1997 and 2002 with the development of the ICU Liaison Nurse (ICU LN) post, medical readmissions to ICU were reduced from 2.3 to 0.5%. It is now 5 years since the position was introduced and the role has evolved over this time so that today the ICU LN not only bridges the gap between ICU and ward-based care, but when necessary can be involved in the care of patients on the ward whose condition has deteriorated to the point where transfer into ICU may be necessary.

Australia↗
PubMedDate not supplied

Staff experiences of an early warning indicator for unstable patients in Australia.

The objective of this study is to explore nursing and medical staff's perceptions of a clinical marker referral tool implemented to assist in the early identification of unstable patients in the general surgical and medical ward environment. A descriptive, exploratory survey design was undertaken 6 months after the implementation of a clinical marker referral tool. The target population for the survey was all ward nursing, junior medical staff and intensive care unit (ICU) registrars in a metropolitan tertiary referral hospital in Australia. The survey consisted of open-ended and closed-ended questions, as well as statements asking participants to explore their perceptions, attitudes and perceived understanding of the clinical marker referral tool. The surveys were sent to all targeted staff in a personally addressed envelope via the internal mail system. Overall, nursing and medical staff (n = 178) responses were positive to the clinical marker project/tool, offering clear guidelines for staff to respond to the patient's clinical condition and contact the medical staff and the ICU liaison team as appropriate. Furthermore, comments were made in relation to the ICU liaison team acting as a 'support' and 'prompt back-up' for nursing staff when needed. However, ward medical staff had reservations with the clinical markers chosen and with ward nurses being able to contact the ICU registrar after hours. Additionally, the ICU registrars commented on an increase to their workload in having to review unstable patients after hours. These results suggest that the ward nurses required additional support and guidance in caring for the unstable patient in the ward which may improve patient outcomes. Further research investigating the less-favourable responses of the ward medical staff and ICU medical staff is warranted.

Acute Disease↗